| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
31,730,000 |
| Market
Cap: |
5.47(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$79.22 - $172.36 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. Co. focuses on therapeutics for the treatment of diseases with few or no approved therapies. Co.'s main programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease. Co.'s primary product candidates include bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich's ataxia. Both bardoxolone and omaveloxolone activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
264,142 |
598,993 |
| Total Sell Value |
$0 |
$0 |
$35,074,334 |
$63,982,389 |
| Total People Sold |
0 |
0 |
9 |
10 |
| Total Sell Transactions |
0 |
0 |
33 |
53 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ruff Shamim |
Director |
– • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,359) |
0 |
|
- |
|
| Huff James Warren |
Chief Executive Officer |
• • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,398) |
0 |
|
- |
|
| Huff James Warren |
Chief Executive Officer |
• • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(122,480) |
0 |
|
- |
|
| Loewen Andrea |
SVP, Global Regulatory Affairs |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,416) |
0 |
|
- |
|
| Patni Rajiv |
EVP, Chief R&D Officer |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(45,000) |
0 |
|
- |
|
| Wortley Michael D |
Chief Legal Officer |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(49,701) |
0 |
|
- |
|
| Soni Manmeet Singh |
COO, CFO and President |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(62,621) |
0 |
|
- |
|
| Ryder Steven |
Director |
– • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,907) |
0 |
|
- |
|
| Meyer Colin John |
Chief Innovation Officer |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(81,633) |
0 |
|
- |
|
| Bir Dawn Carter |
Chief Commercial Officer |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(33,805) |
0 |
|
- |
|
| Oliger Christy J. |
Director |
– • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,565) |
0 |
|
- |
|
| Edwards Martin |
Director |
– • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,116) |
0 |
|
- |
|
| Mcgaughy R Kent Jr |
|
• • • |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,901,772) |
0 |
|
- |
|
| Mcgaughy R Kent Jr |
|
• • • |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,004) |
0 |
|
- |
|
| Rose William |
Director |
– • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(568,170) |
0 |
|
- |
|
| Rose William |
Director |
– • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(31,413) |
0 |
|
- |
|
| Anand Bhaskar |
SVP, Chief Accounting Officer |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(24,089) |
0 |
|
- |
|
| Mcclellan William D. Jr. |
Director |
– • – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,017) |
0 |
|
- |
|
| Loewen Andrea |
SVP, Global Regulatory Affairs |
• – – |
2023-09-14 |
4 |
S |
$172.03 |
$546,181 |
D/D |
(3,175) |
28,416 |
|
-0% |
|
| Anand Bhaskar |
SVP, Chief Accounting Officer |
• – – |
2023-09-05 |
4 |
S |
$169.20 |
$68,695 |
D/D |
(406) |
24,089 |
|
-2% |
|
| Rose William |
Director |
– • – |
2023-08-23 |
4 |
GD |
$0.00 |
$0 |
I/I |
500,000 |
379,281 |
|
- |
|
| Meyer Colin John |
Chief Innovation Officer |
• – – |
2023-08-16 |
4 |
S |
$168.74 |
$100,569 |
D/D |
(596) |
81,633 |
|
-2% |
|
| Soni Manmeet Singh |
COO, CFO and President |
• – – |
2023-08-16 |
4 |
S |
$168.41 |
$295,566 |
D/D |
(1,755) |
62,621 |
|
-2% |
|
| Anand Bhaskar |
SVP, Chief Accounting Officer |
• – – |
2023-08-16 |
4 |
S |
$168.42 |
$35,368 |
D/D |
(210) |
24,495 |
|
-2% |
|
| Bir Dawn Carter |
Chief Commercial Officer |
• – – |
2023-08-16 |
4 |
S |
$168.33 |
$66,996 |
D/D |
(398) |
33,805 |
|
-2% |
|
393 Records found
|
|
Page 1 of 16 |
|
|
